Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,820 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial.
Fujitani K, Shitara K, Takashima A, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Hosaka H, Komatsu Y, Shimada K, Kawabata R, Ohdan H, Kodera Y, Nakamura M, Nakajima TE, Miyata Y, Moriwaki T, Kusumoto T, Nishikawa K, Ogata K, Shimura M, Morita S, Koizumi W. Fujitani K, et al. Among authors: nakamura m. Gastric Cancer. 2021 Mar;24(2):467-476. doi: 10.1007/s10120-020-01131-y. Epub 2020 Nov 2. Gastric Cancer. 2021. PMID: 33136231 Free PMC article. Clinical Trial.
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K. Yamada Y, et al. Among authors: nakamura m. Lancet Oncol. 2013 Dec;14(13):1278-86. doi: 10.1016/S1470-2045(13)70490-X. Epub 2013 Nov 11. Lancet Oncol. 2013. PMID: 24225157 Clinical Trial.
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. Nishikawa K, et al. Among authors: nakamura m. Eur J Cancer. 2015 May;51(7):808-16. doi: 10.1016/j.ejca.2015.02.009. Epub 2015 Mar 18. Eur J Cancer. 2015. PMID: 25797356 Free article. Clinical Trial.
The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
Nakamura M, Yamada Y, Muro K, Takahashi K, Baba H, Sasaki Y, Komatsu Y, Satoh T, Mishima H, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K. Nakamura M, et al. Future Oncol. 2015;11(10):1471-8. doi: 10.2217/fon.15.59. Future Oncol. 2015. PMID: 25963425 Free article. Clinical Trial.
Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.
Sunakawa Y, Yang D, Moran M, Astrow SH, Tsuji A, Stephens C, Zhang W, Cao S, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Masuishi T, Takeuchi M, Fujii M, Nakajima T, Ichikawa W, Lenz HJ. Sunakawa Y, et al. Among authors: nakamura m. Cancer Biol Ther. 2016 Jul 2;17(7):751-9. doi: 10.1080/15384047.2016.1178426. Epub 2016 Apr 22. Cancer Biol Ther. 2016. PMID: 27104867 Free PMC article.
Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).
Tsuji A, Sunakawa Y, Ichikawa W, Nakamura M, Kochi M, Denda T, Yamaguchi T, Shimada K, Takagane A, Tani S, Kotaka M, Kuramochi H, Furushima K, Koike J, Yonemura Y, Takeuchi M, Fujii M, Nakajima T. Tsuji A, et al. Among authors: nakamura m. Target Oncol. 2016 Dec;11(6):799-806. doi: 10.1007/s11523-016-0445-6. Target Oncol. 2016. PMID: 27306648
Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.
Sunakawa Y, Ichikawa W, Tsuji A, Denda T, Segawa Y, Negoro Y, Shimada K, Kochi M, Nakamura M, Kotaka M, Tanioka H, Takagane A, Tani S, Yamaguchi T, Watanabe T, Takeuchi M, Fujii M, Nakajima T. Sunakawa Y, et al. Among authors: nakamura m. Clin Colorectal Cancer. 2017 Sep;16(3):e171-e180. doi: 10.1016/j.clcc.2016.09.010. Epub 2016 Oct 6. Clin Colorectal Cancer. 2017. PMID: 27856123 Clinical Trial.
S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study.
Baba H, Yamada Y, Takahari D, Matsumoto H, Yoshida K, Nakamura M, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K. Baba H, et al. Among authors: nakamura m. ESMO Open. 2017 Mar 9;2(1):e000135. doi: 10.1136/esmoopen-2016-000135. eCollection 2017. ESMO Open. 2017. PMID: 28761727 Free PMC article.
Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).
Kimura Y, Fujii M, Masuishi T, Nishikawa K, Kunisaki C, Matsusaka S, Segawa Y, Nakamura M, Sasaki K, Nagao N, Hatachi Y, Yuasa Y, Asami S, Takeuchi M, Furukawa H, Nakajima T; JACCRO GC-06 Study Group. Kimura Y, et al. Among authors: nakamura m. Gastric Cancer. 2018 May;21(3):421-427. doi: 10.1007/s10120-017-0766-x. Epub 2017 Sep 21. Gastric Cancer. 2018. PMID: 28936560 Free PMC article. Clinical Trial.
14,820 results
You have reached the last available page of results. Please see the User Guide for more information.